Ashland Inc (AHT.MU)
| Previous close | 89.00 |
| Open | 89.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 89.50 - 89.50 |
| 52-week range | 68.50 - 90.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 23 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAshland board authorizes quarterly dividend
WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock which represents a five percent increase from the previous quarter. The dividend is payable on June 15, 2024, to stockholders of record at the close of business on June 1, 2024. As of April 30, 2024, there were 50,128,349 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE: ASH
Business WireTurnspire Capital Partners to Acquire Ashland Nutraceuticals Business
NEW YORK, May 07, 2024--Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has signed a definitive agreement to acquire the nutraceuticals business of Ashland Inc. (NYSE: ASH) ("Ashland Nutraceuticals" or the "Business").
- GlobeNewswire
Ashland signs definitive agreement to sell nutraceuticals business to Turnspire Capital Partners
WILMINGTON, Del., May 07, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC (“Turnspire”). The transaction is expected to close in the calendar third quarter 2024, subject to the satisfaction of customary closing conditions. Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies, as well a
